Replies to post #190795 on Biotech Values

[justrpaul]

Surely, it's but an easily made mistake

and not the real issue. Symphony is not some blogger posting in its collective pajamas, but a real life business dealing with prescriptions.

Their observations of far higher rejections for VPAK coupled with the certainty that ESRX has the the lions share of market share for VPAK should surely raise issues with anyone concerned with the credibility of ESRX or with the forecasts of VPAK sales.